Sponsor & Developer Portfolio
AstraZeneca
Clinical development pipeline, platform architecture, and registered trial tracking for AstraZeneca vaccine candidates.
4
Candidates
4
Target Diseases
5
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 1 Phase 3 Clinical Trial: 1 Phase 2 Clinical Trial: 1 Phase 1 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 4
Target Pathogens & Indications
COVID-19 Influenza Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tuberculosis
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-azd1222-astrazeneca
AZD1222
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2023-04-19 (registry estimate)
Phase 1 Clinical Trial
ctgov-durvalumab-astrazeneca
Durvalumab
Target: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-06-30 (registry estimate)
Phase 2 Clinical Trial
ctgov-azd4117-astrazeneca
AZD4117
Target: Influenza
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-01-28 (registry estimate)
Phase 3 Clinical Trial
ctgov-durvalumab-medi4736-astrazeneca
Durvalumab (MEDI4736)
Target: Tuberculosis
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2025-04-03 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.